The Muscle Warning About GLP-1s Leaves Out What the Placebo Group Did

You have almost certainly heard some version of it by now: these drugs strip your muscle. It is not an invented claim. Lean mass does fall on GLP-1 medication, the trials measured it falling, and the number is not small. What tends to drop out of the retelling is the other column on the same table — what happened to the people in those trials who were given a placebo.

Photo by Polina Tankilevitch on Pexels

SURMOUNT-1 tested tirzepatide against placebo. A body-composition substudy took 160 of its 2,539 participants — 124 on pooled tirzepatide doses, 36 on placebo, 73 percent of them women, average starting weight 102.5 kg — and scanned them with DXA, which separates fat mass from lean mass, at the start and again at week 72. Over those 72 weeks the tirzepatide group lost 21.3 percent of body weight, 33.9 percent of fat mass and 10.9 percent of lean mass. The placebo group lost 5.3 percent of body weight, 8.2 percent of fat mass and 2.6 percent of lean mass.

Photo by Artem Podrez on Pexels

Divide it out and the same figure lands in both columns. Roughly 75 percent of the weight lost was fat and roughly 25 percent was lean tissue — on the drug and on the placebo alike. That is worth being careful about in both directions. It does not show that losing a quarter of your lost weight as lean mass is harmless; that is a separate question and the substudy does not answer it. What it shows is narrower and still useful: that ratio does not appear to be something the drug does. It is closer to what accompanies weight loss generally, at whatever speed you get there.

Photo by Pavel Danilyuk on Pexels

There is a second question underneath the first, and far fewer studies have gone after it: does the lean mass that disappears take function with it? The SEMALEAN study, published in Diabetes, Obesity and Metabolism in 2025, followed 106 patients on semaglutide for twelve months with scans at baseline, seven months and twelve. Fat mass fell 18.9 percent by the end. Lean mass dropped 3.0 kg by month seven and then stopped falling. Grip strength, meanwhile, went up — by 3.7 kg at seven months and 4.1 kg at twelve. The share of participants meeting the criteria for sarcopenic obesity, meaning low muscle function alongside high body fat, fell from 49 percent to 33 percent.

Here is the part that a headline would skip. SEMALEAN is a cohort study: it followed one group of people over time and had no comparison group who did something else. That design cannot establish what caused what. People who start a medication like this frequently change several things at once, and any of those could be doing the work. So the honest reading is not "the drug makes you stronger." It is narrower, and it is still the most interesting thing in the paper: lean mass fell while measured strength rose, in the same people, over the same year. Whatever else that means, it means a kilogram figure on a scan is a poor stand-in for what a body can actually do.

Several things remain genuinely open. Nobody has good long-term data on what happens to lean mass and function after someone stops taking these drugs. Older patients, who have less muscle to begin with and more to lose, are underrepresented in the substudies. And the advice now circulating everywhere — that resistance training and enough protein cancel the lean-mass loss almost entirely — deserves a closer look at where it comes from. The underlying idea is plausible, and clinicians do recommend strength training during weight loss for reasons that predate these drugs by decades. But trace the specific numbers being passed around, the exact grams and the exact weekly session counts, and a striking share of them lead back to companies selling protein powder, supplements or body-composition packages. That does not make them wrong. It does mean they are marketing rather than guidance, and they should be read as such until a professional body puts its name to a figure.